Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Frigault

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
Blood Advances|April 25, 2022
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myelomaMatthew J Frigault, Michael R Bishop, Jacalyn Rosenblatt, et al.
Blood Cancer Discovery|January 11, 2022
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesStefanie R Bailey, Sonika Vatsa, Rebecca C Larson, et al.
Blood|March 31, 2025
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentViktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Defining the role of syndecan-4 in mechanotransduction using surface-modification approachesRobert M Bellin, James D Kubicek, Matthew J Frigault, et al.
Nature Communications|November 18, 2023
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myelomaRebecca C Larson, Michael C Kann, Charlotte Graham, et al.
European Journal of Cancer (Oxford, England : 1990)|October 18, 2021
Immune checkpoint inhibitors for cancer and venous thromboembolic eventsJingyi Gong, Zsofia D Drobni, Raza M Alvi, et al.
Transplantation and Cellular Therapy|January 29, 2023
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell TherapiesSarah Nikiforow, Matthew J Frigault, Noelle V Frey, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Leukemia|July 18, 2020
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapyVinayak Venkataraman, Keagan S Casey, Maristela Onozato, et al.
Cytometry. Part B, Clinical Cytometry|February 28, 2024
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral bloodWon-Ho Lee, Charlotte E Graham, Hadley R Wiggin, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
Blood Advances|April 25, 2022
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myelomaMatthew J Frigault, Michael R Bishop, Jacalyn Rosenblatt, et al.
Blood Cancer Discovery|January 11, 2022
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesStefanie R Bailey, Sonika Vatsa, Rebecca C Larson, et al.
Blood|March 31, 2025
Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentViktoria Blumenberg, Benjamin R Puliafito, Charlotte E Graham, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
Defining the role of syndecan-4 in mechanotransduction using surface-modification approachesRobert M Bellin, James D Kubicek, Matthew J Frigault, et al.
Nature Communications|November 18, 2023
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myelomaRebecca C Larson, Michael C Kann, Charlotte Graham, et al.
European Journal of Cancer (Oxford, England : 1990)|October 18, 2021
Immune checkpoint inhibitors for cancer and venous thromboembolic eventsJingyi Gong, Zsofia D Drobni, Raza M Alvi, et al.
Transplantation and Cellular Therapy|January 29, 2023
Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell TherapiesSarah Nikiforow, Matthew J Frigault, Noelle V Frey, et al.
British Journal of Haematology|August 16, 2023
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvementChristine E Ryan, Rebecca L Zon, Robert Redd, et al.
Leukemia|July 18, 2020
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapyVinayak Venkataraman, Keagan S Casey, Maristela Onozato, et al.
Cytometry. Part B, Clinical Cytometry|February 28, 2024
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral bloodWon-Ho Lee, Charlotte E Graham, Hadley R Wiggin, et al.
Pageof 12